
Price Controls On Doctors Are Costing Patients Dearly
Market Manipulation
Just like the December 2024 continuing resolution, the current budget reconciliation bill fails to address the problem of Medicare reimbursing physicians at below market rates. Without a fix, the inevitable consequences will be worsening doctor shortages, declining healthcare quality, higher overall healthcare spending, and the accelerated loss of independent practices.
Of course, how do we know that Medicare's payments to doctors are below their economic value? To start, Medicare's reimbursement rates have declined relative to both the cost of running a medical practice and inflation.
Doctors consistently report that they lose money treating Medicare patients. A survey of doctors found that Medicare's low reimbursement rates (68%) are a primary threat to independent practices. As for inflation, it has grown 34.5% overall since January 2016 while the prices received by doctors have grown less than half as much - just 15.1%.
This is not due to demand for healthcare declining – remember the huge number of aging Baby Boomers seeking health care – or a huge surge in the number of qualified doctors serving patients. In fact, the level of doctors serving patients today - 25.4 active physicians per 10,000 residents - is down from 2019 and has fallen back to 2009 levels.
The problem is government setting prices at below market levels. And setting prices below market rates cause adverse consequences to our health, such as fewer doctors available to serve patients.
This creates serious health risks for patients including longer wait times for appointments, less access to specialty care, shorter doctor visits, larger numbers of medical errors, and more misdiagnoses or missed diagnoses. These risks are more acute for people living in rural areas, who have a higher chance of living in areas deemed 'medical deserts' or regions that lack sufficient access to pharmacies, primary care providers, and hospitals.
Medicare's uneconomical reimbursement system is also changing how patient care is delivered. For example, under the current reimbursement system, Medicare compensates hospitals more than independent physician offices for performing the same service. This incentivizes independent practices to merge with hospitals. Consolidating lower-cost physician practices into higher-cost hospital systems is driving up overall healthcare costs for patients and taxpayers and is reducing patient choice.
Congress has acknowledged that there are serious consequences from government price controls, enacting legislation to raise provider payments by 2.9% for most of 2024. But these payments went back down on January 1, and the problem continues to plague the healthcare system.
Fixing Medicare's flawed reimbursement policy should be a top priority for Congress. The more efficient reform comprehensively addresses Medicare's broader deficiencies by turning Medicare into a cash-based benefit system that funds health savings accounts (HSAs) for seniors.
This direct payment option allows beneficiaries to receive their Medicare benefits in the same manner that they receive their Social Security benefits. At current spending levels, Medicare could give each beneficiary $15,150 annually to cover their insurance and healthcare costs.
Under this system, patients and physicians, not bureaucrats, would take change and prices would reflect value. Providers would have to compete and would be incentivized to find new and better ways to expand value and reducing costs for patients.
Fundamental reforms that establish well-functioning healthcare and health insurance markets will take time. Given this, Congress could act more immediately to index government payments to medical inflation and stop paying different reimbursement rates for the same services depending on where care is delivered.
With more people aging, taxpayers will be spending more and more for Medicare and Medicaid. Unless Congress acts soon to stop Medicare's underpayment of physicians, it is patients who will ultimately pay the highest price with less access to doctors and specialists and longer wait times for life-saving care.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
GPs can prescribe weight loss jabs on the NHS from today - but strict eligibility criteria in place
GPs will be able to prescribe weight loss jabs on the NHS from today. About 220,000 people with the "greatest need" are set to receive Mounjaro - with strict criteria for the first year of the rollout. Initially, only those with a body mass index of over 40 who have at least four other health problems linked to obesity will be eligible. Some doctors have raised concerns about the additional workload this new programme will bring, while pharmacists fear it could lead to supply shortages. While an estimated 1.5 million people are now taking weight loss drugs across the UK, they could previously only be accessed through specialist services or private prescriptions. Dr Claire Fuller from NHS England said: "We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health - and greater access to weight loss drugs will make a significant difference to the lives of those people." She added: "While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional." The chairwoman of the Royal College of GPs welcomed NHS England's decision to pursue a phased rollout, and said current workloads must be factored in to ensure the jabs can be prescribed safely. Professor Kamila Hawthorne went on to say: "While weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. "We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later." Read more from Sky News:UK and NATO allies to boost defence spending Her remarks were echoed by the National Pharmacy Association's chairman Olivier Picard, who says "prescribing these medications alone misses the point". He argued that they need to be part of a comprehensive strategy that includes lifestyle coaching, exercise and nutritional guidance - but many GPs currently "lack the bandwidth" to provide this support. "As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends - simply because the foundational lifestyle changes weren't addressed," Mr Picard added. Estimates suggest about 29% of the adult population is obese. Health Secretary Wes Streeting says the government "is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay".
Yahoo
42 minutes ago
- Yahoo
More than half of Utahns favor legalizing recreational marijuana: Poll
A majority of Utahns favor legalizing marijuana for recreational use by adults in the state, according to a new poll. The survey conducted in May for the Deseret News and Hinckley Institute of Politics found 53% — 30% strongly and 23% somewhat — support legalization, while 43% oppose it. In addition, the poll shows 77% support Utah's current medicinal marijuana law, which has been in place since 2018. HarrisX conducted the online poll of 805 registered Utah voters May 16-21. It has a margin of error of plus or minus 3.5 percentage points. Utahns' opinions of recreational marijuana have shifted the past few years. A 2016 poll conducted by Dan Jones & Associates showed only 22% favored legalizing marijuana for recreational use, while 77% opposed making it legal. An April 2023 Deseret News/Hinckley Institute poll found 40% believe marijuana should be legal for both recreational and medical use, while 51% say it should be medical only. The survey also showed nearly 4 in 10 Utahns were concerned medical cannabis could lead to legal recreational use, while about 6 in 10 did not share that concern. There's currently no campaign to legalize marijuana for recreational use, and Utah legislative leaders say they would oppose such an effort. In 2014, the Utah Legislature passed what's known as Charlee's law allowing the use of cannabidiol, or CBD, to treat epileptic seizures. Four years later, voters narrowly approved a ballot initiative extending the use of cannabis for other health conditions amid opposition from the Utah Medical Association, Salt Lake Chamber, Utah Episcopal Diocese, The Church of Jesus Christ of Latter-day Saints and law enforcement. State lawmakers rewrote the law and passed a negotiated bill soon after the public vote. As of May, Utah had 15 medical cannabis pharmacies statewide, including several that make home deliveries. Cumulative sales since the first pharmacy opened in 2020 are approaching $600 million, according to the Utah Department of Health and Humans Services' Center for Medical Cannabis. Just over 101,200 residents have active medical cannabis cards, the vast majority issued to treat persistent pain, with PTSD and cancer a distant second and third, respectively. Utah Senate President Stuart Adams expressed opposition to Utah expanding beyond medicinal use. 'Utah already has a responsible, well-balanced and effective program that ensures individuals with chronic pain or serious illnesses have access while maintaining strong safeguards to prevent misuse. States that have expanded legalization beyond medical use have seen serious social consequences, including increased homelessness and criminal activity. I oppose further expansion because our focus should remain on what truly benefits our state and the well-being of all Utahns,' the Layton Republican said in a statement to the Deseret News. Utah House Speaker Mike Schultz, R-Hooper, also opposes recreational marijuana. 'Our current approach ensures Utahns have access to relief while maintaining important safeguards for public health and safety. I remain firmly opposed to legalizing recreational marijuana. It's encouraging to see that a strong majority of Utahns – 77% – agree that our focus should remain on providing benefit to those who need it most," he said in a statement to the Deseret News. While the Deseret News/Hinckley Institute poll showing a majority of Utahns favor legalized recreational marijuana use might be surprising, it aligns with another recent survey. The results mirror a survey Noble Predictive Insights did for the medical marijuana advocacy group Keep Utah Medical in March. That poll found 52% of Utahns would support a ballot initiative legalizing recreational cannabis in the state, while 38% would not. Alex Iorg, co-founder of the medical cannabis company WholesomeCo as well as co-founder of Keep Utah Medical, commissioned that survey to see where Utahns stood on the recreational issue. 'I guess we're not surprised by those results. That's what we both have found,' he said of the Noble and Deseret News/Hinckley Institute polls. 'But we're seeing this incremental increase of support and I think it's part of this challenge to get medical access. Our hope is that we can improve access to medical cannabis so that we can avoid a recreational ballot initiative." A survey Noble did for the group last October found 50% of Utahns say cannabis should be legal for adults for therapeutic, medical and recreational purposes. Iorg said there's a 'whole herd' of issues that come with recreational marijuana. Medical programs and patients in other states are often 'vilified,' he said, causing people to call for recreational ballot initiatives. In Utah, 'that's a long way off from being successful even at 53%. What we prefer is having a medical program that's supported and focused on medical.' Noble offered this analysis of its poll results: 'YES wins the left and the middle and divides the right. In a red state like Utah, that's enough to get to a solid — though not overwhelming — margin of victory. 'Over the last decade, major political victories came from a populist-traditionalist coalition: The GOP's wings would coalesce, form a majority together, and govern. If legalization were to win, the coalition would be built from left to right — a progressive minority joining with the center and Republican moderates. This is possible — but it requires careful execution.' Currently, 24 states, two U.S. territories and Washington, D.C., legalized marijuana for adult recreational use, according to the National Conference of State Legislatures. Thirty-nine states allow the medical use of cannabis. The Deseret News/Hinckley Institute poll shows much stronger support for legalization among self-identified Democrats and independents than among self-identified Republicans. Nearly three-fourths of Democrats and nearly two-thirds of independents expressed support compared to 43% of Republicans. Broken down by political ideology, 86% of liberals favored legalization, followed by 59% of moderates and 38% of conservatives, according to the poll. Among age groups, 18- to 34-year-olds, showed the highest support at 65%, while those over 65 showed the least at 36%. Support for recreational marijuana legalization exceeds 50% in all four of the Utah congressional districts. It approached 60% in the state's most populous counties, except for Davis and Utah counties at 45% and 43%, respectively. Self-identified members of The Church of Jesus Christ of Latter-day Saints in the poll were decidedly against legalization, with 31% in favor and 66% opposed. Among all self-identified Christians, 43% favor legalization, while 53% oppose it. Men showed stronger support than women, 56% to 50%. Utahns, regardless of political persuasion, overwhelmingly support the state's medical marijuana law — 73% of self-identified Republicans and 80% of self-identified Democrats. Independents came in at 81%, according to the Deseret News/Hinckley Institute poll. The survey also found 69% support for the medical marijuana law among Latter-day Saints and 73% among all Christians. 'It's no longer unacceptable to try cannabis for medical purposes. A lot of people know someone that has benefitted from it directly. There's a lot of exposure to the benefits,' Iorg said. Medical cannabis works and saves lives, he said, adding it's less harmful than prescription opioids. It doesn't solve all the world's problems, he said, but it does help a lot of people, especially those looking for relief. People over 65 showed stronger support for medical marijuana than younger people, but all age groups were above 70%. Support across Utah's congressional districts and most populous counties was also high, the poll shows. Baby boomers are the largest users of cannabis, Iorg said. 'Now, health and wellness is their No. 1 priority and cannabis has shown to be a great tool, especially for pain and sleep.'
Yahoo
2 hours ago
- Yahoo
Here's what to know about the twice-yearly preventative HIV shot
The Food and Drug Administration has approved a twice-yearly preventive HIV shot that could protect millions from the virus. People at risk for HIV may choose to take PrEP, a medication that helps prevent HIV infection. PrEp has been prescribed as a daily pill or a shot given every two months. This new twice-yearly drug called lenacapavir is now the longest-lasting type of PrEP. Ian Haddock, a Houston man who participated in a study of the drug, told The Associated Press it 'expands the opportunity for prevention.' 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' he said. The shot, made by Gilead Sciences, is injected under the skin of the abdomen. It leaves a small 'depot' of medication that slowly absorbs into the body. 'This really has the possibility of ending HIV transmission,' Greg Millett, public policy director at amfAR, The Foundation for AIDS Research, told the AP. But the upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said "gaping holes in the system" in the U.S. and globally "are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' even as little as twice a year. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. Gilead didn't immediately announce its price. The drug only prevents HIV transmission – it doesn't block other sexually transmitted diseases. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities, had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' 'Everyone in every country who's at risk of HIV needs access to PrEP,' Dr. Gordon Crofoot of Houston, who helped lead the study in men, told the AP. 'We need to get easier access to PrEP that's highly effective like this is.'